Please upgrade your browser.
Cancer sufferers have accused the Government's drugs watchdog of condemning patients to an "early death" by denying them new treatments.
The Liberals said the average drug treatment for kidney cancer costs $6,000 to $7,000 per month.
Cash would help cover cost for Canadians with chronic, dire illness.
An intravenous bisphosphonate, Zometa(R) is the only therapy to demonstrate efficacy in reducing or delaying bone complications across a broad range of tumour types such as breast, prostate, lung and renal cell cancers.
Van Andel Institute (VAI) researchers have identified unique DNA changes in each of several types of renal cell carcinoma (RCC), the most common form of kidney cancer in adults. These findings could aid in the diagnosis of these cancers since the many types of RCC are currently identified only by their appearance.
Despite these horror stories, Congress is trying to create a similar agency right here in the United States.
Pfizer announced that important study results involving the company's leading anticancer agent, Sutent (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12-16 September 2008.
AGS-003 to be tested in combination with sunitinib.
Earn $150 for participation.
The spiralling cost of drugs presents an unavoidable challenge.
|Powered by NeonCRM|